Regulatory actions won't stop growth of emerging markets, says Sanofi EVP
Emerging markets account for 7% of Sanofi ’s global revenues, driven by its limited product in rare diseases, diabetes and oncology segments.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer & Oncology | Diabetes | Endocrinology | Pharmaceuticals | Rare Diseases